|
|||||
|
|
A 24-week,randomized, double-blind,active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults |
|
| Authors: | Yuan-Di Halvorsen PhD John P. Lock MD Wenjiong Zhou PhD Fang Zhu PhD Mason W. Freeman MD |
| Affiliation: | 1. Translational Medicine Group, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts;2. Diabetes Center of Excellence, Department of Medicine, University of Massachusetts, Worcester, Massachusetts;3. Hopkins Consulting LLC, Philadelphia, Pennsylvania;4. Syneos Health, Blue Bell, Pennsylvania |
| Abstract: | |
| Keywords: | bexagliflozin body mass fasting plasma glucose HbA1c safety sodium-glucose co-transporter-2 inhibitor systolic blood pressure tolerability |